Pulmatrix Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Peter Ludlum

Chief executive officer

US$510.2k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure4.8yrs

Recent management updates

Recent updates

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Aug 02
There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22
Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29
Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16
Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14
Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27
We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11
We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

CEO

Peter Ludlum (69 yo)

less than a year

Tenure

US$510,224

Compensation

Mr. Peter B. Ludlum, CMA, MBA, served as Interim Chief Financial Officer and Principal accounting & financial officer at Pulmatrix, Inc. since April 18, 2022 until July 20, 2024 and also serves as its Inte...


Board Members

NamePositionTenureCompensationOwnership
Michael Higgins
Independent Chairman9.5yrsUS$92.97k0%
$ 0
David Denning
Member of Pulmazole Clinical Advisory Boardno datano datano data
Christopher Cabell
Independent Director4.5yrsUS$50.56k0%
$ 0
Jonathan Corren
Member of Pulmazole Clinical Advisory Boardno datano datano data
Richard Batycky
Independent Director5.1yrsUS$59.56k0.00068%
$ 149.0
Todd Bazemore
Independent Director4.2yrsUS$58.06k0%
$ 0
Ritesh Agarwal
Member of Pulmazole Clinical Advisory Boardno datano datano data
Cendrine Godet
Member of Pulmazole Clinical Advisory Boardno datano datano data
David Stevens
Member of Pulmazole Clinical Advisory Boardno datano datano data
Michael Wechsler
Member of Pulmazole Clinical Advisory Boardno datano datano data
William Calhoun
Chair of PUR1900 & PUR1800 Clinical Advisory Boardno datano datano data
Stephen Silberstein
Chair of PUR3100 (DHE) Clinical Advisory Boardno datano datano data

4.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: PULM's board of directors are considered experienced (4.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pulmatrix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanDawson James Securities
Andrew FeinH.C. Wainwright & Co.
Anita DushyanthZacks Investment Research Inc.